Nonvitamin,Nonmineral Dietary Supplementation in HIV-Positive People

Abstract

Background: Many consumers with chronic diseases attempt to take control of their health by using dietary supplements. The objective of this study was to describe current nonvitamin, nonmineral (NVNM) supplement use of HIV-infected persons in the Nutrition for Healthy Living (NFHL) cohort, the financial burden that buying these supplements might pose to this population, and to review current literature on potential interactions between NVNM supplements. Methods: At baseline visit, participants were educated by a registered dietitian on keeping a complete 3-day food record (including all supplements) for 2 weekdays and 1 weekend day. Seventy-two subjects reported consumption of NVNM supplements, and their food records were reviewed in detail. Results: Each of the 72 subjects in this study used a mean of 6 NVNM supplements, which may have been in the form of a pill, powder, bar, or liquid. The 6 most common were glutamine (51%), N-acetyl-cysteine (36%), fish oil (33%), α-lipoic acid (32%), acetyl-l-carnitine (28%), and coenzyme Q10 (28%). Participants were also taking an average of 4 vitamin/mineral supplements; the 6 most common were multivitamin/multimineral (83%), vitamin E (51%), vitamin C (47%), vitamin B complex (43%), calcium (29%), and selenium (28%). Conclusions: With a total of 107 different types of NVNM supplements, our estimated cost examples indicated a weekly supplement regimen cost of between $25 and $40 dollars. According to literature review, taking an NVNM supplement may involve some risk because many components have not been studied and these products are not tightly regulated.

Get full access to this article

View all access options for this article.

References

Marcason W. What are some resources that can help my clients sort through conflicting information in dietary supplements? J Amer Diet Assoc. 2003;103:712– 713.

Schaffer DM. Nonvitamin, nonmineral supplement use over a 12-month period by adult members of a large health maintenance organization. J Am Diet Assoc. 2003 ;103:1500– 1504.

Satia-Abouta J, Kristal AR, Patterson RE, Littman AJ, Stratton KL, White E. Dietary supplement use and medical conditions: the VITAL study. Am J Prev Med. 2003 ;24:43– 51.

Anderson W, O'Connor BB, MacGregor RR, Schwartz JS. Patient use and assessment of conventional and alternative therapies for HIV infection and AIDS. Aids. 1993 ;7:561– 565.

Hand R. Alternative therapies used by patients with AIDS. N Engl J Med. 1989 ;320:672– 673.

Hsiao AF, Wong MD, Kanouse DE, et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr. 2003 ;33:157– 165.

Hendricks K, Sansevero M, Houser R, Tang A, Wanke C. Dietary supplement use and nutrient intake in HIV-infected persons. AIDS Read. 2007;17:211– 216, 223–227.

Shabert JK, Winslow C, Lacey JM, Wilmore DW. Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition. 1999 ;15:860– 864.

Huffman FG, Walgren ME. L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals. HIV Clin Trials. 2003;4:324– 329.

10.

Sbrana E, Paladini A, Bramanti E, Spinetti MC, Raspi G. Quantitation of reduced glutathione and cysteine in human immunodeficiency virus-infected patients. Electrophoresis. 2004 ;25:1522– 1529.

11.

Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS. 1997;11:1689– 1697.

12.

Breitkreutz R, Pittack N, Nebe CT, et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med. 2000 ;78:55– 62.

13.

Wohl D, Tien H-C, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005 ;41:1498– 1504.

14.

Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease: fishing for a natural treatment. BMJ. 2004 ;328:30– 35.

15.

Covington M. Omega-3 fatty acids. Am Fam Physician. 2004;70:133– 140.

16.

Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol. 2003 ;14:9– 14.

17.

Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 ;21:114– 121.

18.

Merin JP, Matsuyama M, Kira T, Baba M, Okamoto T. Alpha-lipoic acid blocks HIV-1 LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett. 1996 ;394:9– 13.

19.

Pande V, Ramos MJ. Nuclear factor kappa B: a potential target for anti-HIV chemotherapy. Curr Med Chem. 2003 ;10:1603– 1615.

20.

Hart AM, Wilson AD, Montovani C, et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004 ;18:1549– 1560.

21.

Di Marzio L, Moretti S, D'Alo S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol. 1999 ;92:103– 110.

22.

Bonakdar R, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005;72:1065– 1070.

23.

Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev. 1998 ;3:410– 421.

24.

Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139– 143.

25.

Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 2000 ;355:547– 548.

26.

Palmer ME, Haller C, McKinney PE, et al. Adverse events associated with dietary supplements: an observational study. Lancet. 2003;361:101– 106.

27.

Southwell H, Valdez H, Lederman M, Gripshover B. Use of alternative therapies among HIV-infected patients at an urban tertiary care center. J Acquir Immune Defic Syndr. 2002 ;31:119– 120.

28.

Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products: United States, Germany, and Switzerland, 1999–2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065– 1067.

29.

Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Int Med. 1998;158:2200– 2211.

30.

Winslow LC, Kroll DJ. Herbs as medicines. Arch Intern Med. 1998;158:2192– 2199.

31.

Timbo BB, McCarthy PV, Lin C-TJ. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc. 2006;106:1966– 1974.